Understand the source comparison
SS-LUP-332 Discontinuation: Taper vs Abrupt Cessation
Abrupt Cessation 0 days taper, immediate stop Metabolic rate drops 8–14% within 7–10 days; thyroid suppression persists 14–21 days High. 60–75% of subjects regain 3–7% body weight within 30 days Appropriate only when adverse events require immediate discontinu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Abrupt Cessation
- 0 days taper, immediate stop
- Metabolic rate drops 8–14% within 7–10 days; thyroid suppression persists 14–21 days
- High. 60–75% of subjects regain 3–7% body weight within 30 days
- Appropriate only when adverse events require immediate discontinuation; otherwise creates preventable rebound
- 2-Week Taper
- Reduce dose by 50% for week 1, 25% for week 2, then stop
- Gradual metabolic normalization; partial mitochondrial adaptation maintained through taper
- Moderate. 30–40% experience mild rebound (1–3% weight regain)
- Minimum acceptable protocol for planned cessation; balances timeline with metabolic stability
- 4-Week Taper
- Reduce dose by 25% weekly over 4 weeks
- Smoothest metabolic transition; thyroid axis begins recovery during taper; mitochondrial downregulation is gradual
- Low. Fewer than 20% show rebound when combined with caloric adjustment
- Preferred method for long-duration protocols (16+ weeks) or when metabolic stability is research-critical
- The taper allows thyroid signaling to resume while mitochondrial mass gradually declines, preventing the sudden expenditure drop that drives rebound. A 4-week taper reduces metabolic rate by approximately 2–3.5% per week instead of 8–14% in a single step, giving researchers time to adjust caloric intake downward in parallel with falling expenditure.
- Abrupt cessation is a metabolic shock protocol—reserved for situations where continuing the peptide presents greater risk than stopping immediately. Examples include sustained tachycardia unresponsive to dose reduction, persistent hyperthermia, or planned pregnancy where washout timeline becomes critical. In every other scenario, tapering produces superior outcomes.
- Here's the honest answer: researchers who stop taking SS-LUP-332 abruptly almost always regain weight in the first month post-cessation. Not because the peptide "stopped working"—but because they didn't account for the 200–350 calorie daily expenditure gap that opens when mitochondrial uncoupling ends. Caloric intake that produced a deficit during peptide use becomes maintenance or surplus within 10 days of stopping. The compound didn't fail. The discontinuation plan did.